More conversations, either one on one or in groups via telephone or virtually, along with in-person household activities…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
Dosing has begun in a Phase 2 clinical trial evaluating aTyr Pharma’s efzofitimod, a first-in-class therapy for people with…
The U.S. Food and Drug Administration (FDA) has cleared Cabaletta Bio’s request to begin clinical testing of CABA-201,…
The levels of two microRNAs are found altered in the bloodstream of adults with systemic sclerosis (SSc) compared with…
People with systemic sclerosis (SSc) have a wide range of support and information needs, regardless of their disease duration,…
Bloodstream levels of a protein that plays a role in the body’s response to low oxygen may be an effective…
Plasma exchange helped reduce high blood pressure linked to scleroderma renal crisis (SRC) — a potentially life-threatening complication marked…
Elevated activity of a blood-clotting protein called Factor XIII (FXIII) in the bloodstream of adults with systemic sclerosis (SSc)…
Caregivers of children with juvenile scleroderma cited a lack of knowledge about the rare disease within the medical community…
Levels of microparticles, tiny molecule-filled sacs shed from cells, were altered in the bloodstream of adults with systemic sclerosis…